HOME >> MEDICINE >> NEWS
Patients should be consulted before dialysis treatment begins

to which treatment is better. What patients value about their quality of life should be a factor in the choice of different treatments. Physicians should be doing what is best for each individual patient's quality of life."

Over 900 patients (698 hemodialysis; 230 peritoneal) in 19 states were enrolled in the Choices for Health Outcomes in Caring for ESRD study (CHOICE), a national, prospective cohort study from 1995-1998. Dr. Wu and his colleagues developed the CHOICE Health Experience Questionnaire (CHEQ) to comprehensively measure quality of life of patients on dialysis using patients' reports of the importance they attach to different aspects of their life. Using the CHEQ they assessed self-reported health-related quality of life at the onset of dialysis therapy and one year later. The researchers looked at general domains, or the aspects of life anyone might be concerned about, such as physical and social functioning, and ESRD specific domains, which are problems specific to dialysis patients, such as diet restrictions, body image and problems with dialysis catheters.

The researchers found that both hemodialysis and peritoneal dialysis patients had improvement in nearly all aspects of general functioning and well-being. However, peritoneal dialysis patients did better in some areas of quality of life while hemodialysis patients did better in others. Peritoneal dialysis patients had improvement in their finances. Hemodialysis patients had improvements in physical functioning and general health perceptions, and better sleep.

A report by some of the same Johns Hopkins researchers was recently published in the Feb. 11 issue of the Journal of the American Medical Association. They found that when compared to the more common hemodialysis, peritoneal dialysis patients were 1.5 times more likely to rate their overall care as excellent. Dr. Wu explained that this latest study looked at the quality of life patients experienced at the start of dia
'"/>

Contact: Kenna L. Brigham
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
1-Mar-2004


Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Patients should consulted before dialysis treatment begins

(Date:10/22/2014)... (PRWEB) October 22, 2014 On October ... Minds featuring skin diseases both fictional and real. ... (CEHMDF), a nonprofit organization committed to advocacy and philanthropy ... CBS will take the opportunity to impart truth and ... , There are many misconceptions about Morgellons ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is ... extension of her life’s mission. Her extensive experience in the ... of FirstLight HomeCare, make it clear that Hunter’s mission is ... my work makes a difference in the lives of others,” ... after much research, I felt ready to start on this ...
(Date:10/22/2014)... Kentucky (PRWEB) October 22, 2014 Shriners ... agreement that will change the current location of Shriners ... to South Limestone across from the University of Kentucky ... a state-of-the-art ambulatory care center, owned and operated by ... the orthopaedic needs of children and their families well ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
Cached News: